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ABSTRACT
Objective We have reported previously that the IRAK4 
inhibitor PF06426779 given to ubiquitin- binding- defective 
ABIN1[D485N] mice at 6 weeks of age prevents the major 
facets of lupus that develop 10 weeks later. The present 
study was undertaken to investigate whether PF06426779 
could reverse the lupus phenotype when administered 
to 13- week- old ABIN1[D485N] mice that had already 
developed symptoms of lupus.
Methods Splenomegaly, the number of splenic 
neutrophils, TFH and Germinal Centre B (GCB) cells, serum 
levels of immunoglobulins, the extent of kidney, liver 
and lung pathology, and glomerular IgA and IgM were 
measured after feeding 13- week- old ABIN1[D485N] and 
wild- type mice for another 10 weeks with R&M3 diet with 
and without PF06426779 (4 g/kg).
Results Following drug treatment, spleen size and weight, 
splenic neutrophil numbers, and serum IgA and glomerular 
IgA levels of ABIN1[D485N] mice returned to those seen in 
wild- type mice. The rise in splenic TFH and GCB numbers, 
the increase in kidney and liver pathology, and the 
concentrations of serum IgG1, IgG2A and IgE between 13 
and 23 weeks were suppressed. There was no reduction 
in the level of anti- self double- stranded DNA, anti- self 
nuclear antigens or IgM during the drug treatment.
Conclusions The results demonstrate the therapeutic 
potential of IRAK4 inhibitors for the treatment of lupus and 
raise the possibility of monitoring efficacy by measuring 
decreases in the serum levels of IgA. Our results support 
the view that there may be a closer connection between 
lupus and IgA nephropathy than realised previously.
INTRODUCTION
ABIN1 (A20- binding inhibitor of NF-κB 1) is 
a polyubiquitin- binding protein that restricts 
the production of inflammatory mediators by 
the innate immune system. Polymorphisms 
in TNIP1, the gene encoding ABIN1, predis-
pose to lupus in many human populations 
(reviewed,1), and mice deficient in ABIN12 or 
expressing a polyubiquitin- binding- deficient 
mutant of ABIN1 (ABIN1[D485N])3 develop 
a disease resembling type III/IV human 
lupus nephritis.4 All the major facets of lupus 
in ABIN1[D485N] mice can be prevented 
by crossing ABIN1[D485N] mice to mice 
expressing the kinase- inactive IRAK4[D329A] 
mutant5 or by oral administration of the small 
molecule IRAK4 inhibitor PF 06426779 prior 
to the appearance of the hallmark features 
of lupus, such as glomerulonephritis, liver 
and lung inflammation, and increased levels 
of autoantibodies.6 A different IRAK4 inhib-
itor (BMS- 986126) was also shown to prevent 
kidney pathology in the lupus- prone MRL/
lpr and NZB/W mouse lines.7
Lupus is usually diagnosed when humans 
have already developed the disease. To eval-
uate the potential of the IRAK4 inhibitor 
for the treatment of lupus, it was therefore 
critical to investigate whether it prevented 
the further rise, or even reversed, the hall-
mark features of lupus after they had already 
Key messages
What is already known about this subject?
 ► Polymorphisms in TNIP1, the gene encoding encod-
ing ABIN1 (A20- binding inhibitor of NF-κB 1), predis-
pose to lupus in many human populations.
 ► Ubiquitin- binding- deficient ABIN1[D485N] knock- in 
mice spontaneously develop a lupus- like disease, 
which is driven by the TLR7- MyD88- IRAK4 pathway.
What does this study add?
 ► The IRAK4 inhibitor PF06426779 reverses spleno-
megaly, neutrophil numbers and the rise in serum 
and glomerular IgA levels in ABIN1[D485N] mice that 
have already developed symptoms of lupus, and pre-
vents further increases in splenic T
FH and Germinal 
Centre B cell numbers, serum IgG1 and IgE concen-
trations, and kidney and liver pathology.
How might this impact on clinical practice or future 
developments?
 ► The study suggests that IRAK4 inhibitors may have 
therapeutic potential for the treatment of lupus.
 ► It also indicates that monitoring the serum levels of 
IgA, as well as patrolling monocyte numbers in the 
blood, may be a simple non- invasive way to examine 
drug efficacy, and may reveal whether IgA nephrop-
athy and SLE are the same disease.
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developed. Here, we present the results of such a study 
in ABIN1[D485N] mice, which has revealed some inter-
esting and unexpected findings.
METHODS
ABIN1[D485N] mice aged 13 weeks that had already 
developed splenomegaly, autoimmunity and organ 
inflammation, or control wild- type littermates, were 
fed for 10 weeks on chow containing the IRAK4 inhib-
itor PF06426779 or control chow. The sources of other 
reagents and the methods used are described elsewhere.6
Statistical analysis was carried out using GraphPad 
Prism 9 software. The distribution was determined using 
the Shapiro- Wilk normality test. Multiple comparisons of 
data with normal distribution were performed using one- 
way ANOVA followed by Tukey’s post hoc test. Multiple 
comparison of non- parametric data was done using the 
Kruskal- Wallis test, followed by the Mann- Whitney U test. 
Data in percentages were logit- transformed. Figures were 
drawn using GraphPad Prism and Adobe Illustrator.
Immunohistochemistry
Kidney sections were stained with haematoxylin and 
either anti- IgA (Abcam, ab97231) or anti- IgM (Abcam, 
ab97226) primary antibodies at 1:1600 dilution. The 
signal was detected using ImmPRESS[R] HRP Horse 
Anti- Goat IgG Polymer Detection Kit (Vector Laborato-
ries). Slides for microscopy were scanned using Motic 
EasyScan Infinity at ×40 magnification and analysed using 
QuPath software. Forty glomeruli per mouse were gated 
and those staining positively with 3,3′-diaminobenzidine 
were quantified.
RESULTS AND DISCUSSION
The IRAK4 inhibitor PF06426277 was given to 
ABIN1[D485N] mice in their food (4 g/kg) from 13 
weeks. At this age, splenomegaly, autoimmunity and 
organ inflammation have already started to develop. 
Strikingly, 10 weeks after treatment with PF06426779 
had commenced, the spleen size had almost returned to 
that seen in wild- type mice (figure 1A) and neutrophil 
numbers had also normalised (figure 1B). Splenic TFH 
and Germinal Centre B (GCB) cell numbers continued 
to increase over the 10- week period in ABIN1[D485N] 
mice not given the drug, but this was prevented by the 
IRAK4 inhibitor (figure 1C,D). Importantly, the further 
rise in kidney and liver pathology from 13 to 23 weeks was 
suppressed, but not lung pathology (figure 2A–F).
ABIN1[D485N] mice display elevated levels of 
patrolling monocytes in their blood at only 4 weeks, 
which increases progressively up to 16 weeks. PF06426779 
administered from 6 weeks prevented the subsequent 
rise in pMo seen in the absence of PF06426779.6 Here, 
we found that PF06426779 administered from 13 weeks 
reduced the number of pMo after 18 or 23 weeks, but 
not to the level seen in control WT mice (online supple-
mental figure S1).
The kidneys of ABIN1[D485N] mice contain deposits 
of complement factors and immunoglobulins (IgA, 
Figure 1 Reversal of splenic phenotypes in ABIN1[D485N] knock- in mice by an IRAK4 inhibitor. 13- week- old ABIN1[D485N] 
mice (n=6) and age- matched wild- type (WT) (n=5) mice were fed for 10 weeks on R&M3 diet containing or not containing PF 
06426779 (4 g/kg). Mice were culled at the age of 23 weeks. An additional group of 8 WT and 6 ABIN1[D485N] knock- in mice 
were culled when they were 13 weeks old as a control. (A) Spleen weight and a representative image showing relative spleen 
size. Bar equals 1 cm. (B) Neutrophil numbers in the spleen. (C) Germinal Centre B cell numbers in the spleen. (D) Follicular T 
helper cell numbers in the spleen. Each symbol shows the result from a single individual mouse. Statistical significance was 
calculated using one- way ANOVA and Tukey’s post hoc test (A, B and D) or the Kruskal- Wallis and the Mann- Whitney U tests 
(C); * denotes p<0.05, ** denotes p<0.01 and *** denotes p<0.001. The methodology used is detailed in Nanda et al.6
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IgM and IgG) at 5–6 months of age.4 We therefore 
measured the levels of these and other immunoglobulins 
in the serum of ABIN1[D485N] mice (figure 3). At 13 
weeks, IgA, IgM, IgG2a and IgG2b levels were elevated 
(figure 3A–C), but IgG1 and IgE were not (figure 3E,F). 
Treatment of ABIN1[D485N] mice for 10 weeks with the 
IRAK4 inhibitor reversed the rise in serum IgA seen at 
13 weeks of age, the levels returning to those measured 
in WT mice (figure 3A). In contrast, serum levels of IgM 
and IgG2b measured at 13 weeks in ABIN1[D485N] mice 
were not reduced after 10 weeks of IRAK4 inhibitor treat-
ment (figure 3B,C). The serum levels of IgM continued 
to increase between 13 and 23 weeks in ABIN1[D485N] 
mice whether or not the mice were treated with the IRAK4 
inhibitor. In contrast, the further rise in serum IgG2a 
observed between 13 and 23 weeks in ABIN1[D485N] was 
prevented by the drug (figure 3D).
Serum IgG1 and IgE levels were not elevated in 
13- week- old ABIN1[D485N] mice but were greatly 
elevated after 23 weeks (figure 3E,F). Similar to IgG2a, 
this rise between 13 and 23 weeks was prevented by 
administration of the IRAK4 inhibitor (figure 3E,F).
The lack of effect of the drug on serum IgM and IgG2b 
levels does not appear to be explained by much longer 
Figure 2 Effect of the IRAK4 inhibitor PF 06426277 on organ inflammation. (A–C) Representative histological images showing 
H&E staining of the glomerulus (A), liver (B) and lungs (C) of 13- week- old ABIN1[D485N] knock- in mice, 23- week- old WT and 
ABIN1[D485N] mice fed on R&M3 control diet for 10 weeks, and 23- week- old ABIN1[D485N] mice fed on R&M3 diet containing 
PF 06426779 (4 g/kg). (D–F) As in A–C, except that the graphs show the pathology scores of the kidney (D), liver (E) and lungs 
(F). The horizontal bars equal 50 µm in (A) and 100 µm in (B) and (C). Each symbol shows the result from a single individual 
mouse. Statistical significance was calculated using the Kruskal- Wallis and the Mann- Whitney U tests; * denotes p<0.05 
and **p<0.01. In D–F, an ordinal grading scale from 0 to 4 was used to assess the pathology observed semi- quantitatively, 
where 0=absent, 1=mild, 2=moderate, 3=marked and 4=severe. In the images of the kidney sections, glomerulonephropathy, 
tubulointerstitial fibrosis, inflammatory cell infiltrates, basophilic tubules and protein cast were all scored separately. The five 
scores were then added together to produce a cumulative pathology score shown on the ordinate (D). Similarly, for the liver 
sections, the presence of perivascular, periportal and parenchymal inflammatory cell infiltrates, increased cellularity and oval cell 
hyperplasia were scored separately and the values combined (E), and for the lung sections, the peribronchiolar and perivascular 
inflammatory cell infiltrates, subpleural lymphoid focus and bronchus- associated lymphoid tissue were scored separately and 
the values combined (F). The pathologist (CS) carried out the scoring blind without knowledge of the identity of each sample.
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half lives of these immunoglobulins in the blood. In 
normal adult mice, all the immunoglobulins studied have 
half lives of days and not weeks or months. The half lives 
of IgM and IgG2b are 2 and 4–6 days, respectively, shorter 
than IgG1 (6–8 days),8 but longer than IgA and IgE (1 
day8 and 0.5 day,9 respectively).
Interestingly, the 10- week treatment with the IRAK4 
inhibitor did not affect serum levels of ANA signifi-
cantly (figure 3G) or anti- dsDNA (figure 3H) observed 
after 23 weeks. The reversal of splenomegaly and splenic 
neutrophil levels, the prevention of the further rise in 
splenic TFH and GCB cell numbers, and the improved 
kidney and liver pathology over this period following 
treatment with the IRAK4 inhibitor therefore occurred 
without any significant change in the serum levels of the 
autoantibodies examined.
Of all the antibodies studied, the effect of the IRAK4 
inhibitor on serum IgA levels showed the strongest 
correlation with the appearance and disappearance of 
splenomegaly and splenic neutrophil numbers between 
13 and 23 weeks of age. Consistent with these findings, 
glomerular IgA was also reduced by feeding 13- week- old 
ABIN1[D485N] mice for 10 weeks with diet containing 
06426779, but IgM was not (online supplemental figure 
S2). Interestingly, the deposition of IgA in the kidney, 
termed IgA nephropathy (IgAN), is the most frequent 
primary glomerulopathy in the world. Although the co- as-
sociation of SLE and IgAN had been reported in several 
human patients, the possibility that IgA deposition might 
be a subtype or even a primary trigger of kidney pathology 
in human SLE had not been considered until a patient 
diagnosed with SLE was found to contain glomerular IgA 
deposits.10 The ABIN1[D485N] mice also accumulate 
glomerular IgA deposits.4 Since IgAN and SLE are both 
relatively common conditions, it is possible that their 
co- existence is underdiagnosed.
Four IRAK4 inhibitors have entered clinical trials for 
the treatment of rheumatoid arthritis, psoriasis and 
lymphoma with little evidence of toxicity.11 The present 
study suggests that IRAK4 inhibitors may also have thera-
peutic potential for the treatment of some types of lupus 
and that it may be possible to monitor their efficacy 
rapidly and non- invasively by measuring the serum levels 
of IgA and/or other immunoglobulins, such as IgG1 or 
IgE or by a decrease in patrolling monocyte numbers. 
The routine monitoring of serum IgA levels in patients 
with lupus patients may also reveal whether IgAN and 
SLE are really the same disease.
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ABIN1[D485N] knock- in mice. (A) IgA; (B) IgM; (C) IgG2b; (D) 
IgG2a; (E) IgG1; (F) IgE; (G) ANA; (H) anti- double stranded 
DNA (anti- dsDNA). The measurements were made in wild- 
type and ABIN1[D485N] knock- in mice at the ages indicated. 
Where indicated (+) the R&M3 diet included PF 06426779 
(4 g/kg) from the age of 13 weeks until the mice were culled 
at the age of 23 weeks. Different mouse cohorts were used 
for the studies at 13 and 23 weeks. Each symbol shows the 
result from a single individual mouse. Statistical significance 
was calculated using the Kruskal- Wallis and the Mann- 
Whitney U tests; * denotes p<0.05, ** denotes p<0.01 and *** 
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